Patient’s global assessment of general health by VAS at baseline predicts ACR/EULAR remission after 3, 6 and 12 month’s of efficient treatment in DMARD- and steroid naïve early rheumatoid arthritis patients. The Danish CIMESTRA-study

M. Herly, Kristian Stengaard-Pedersen, P. Vestergaard, Jan Pødenphanth, Mikkel Østergaard, P. Junker, Merete Lund Hetland, Kim Hørslev-Petersen, Torkell Ellingsen

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind71
Udgave nummerSuppl. 3
Sider (fra-til)655
Antal sider1
ISSN0003-4967
StatusUdgivet - 2012

Citationsformater